• American Society of Breast Disease. The use of magnetic resonance imaging of the breast (MRIB) for screening of women at high risk of breast cancer. Dallas (TX): American Society of Breast Disease; 2004 Jun 28. 5 p. [40 references]

This is the current release of the guideline.

1. Magnetic resonance imaging of the breast (MRIB) is an adjunct to mammography, clinical breast examination, and ultrasonography for breast cancer detection in women at high risk of breast cancer based on family history or BRCA mutations.
2. MRIB is not recommended for breast cancer screening in the general population.
3. Although published studies have evaluated yearly screening in conjunction with mammography, clinical breast examination, and in some cases, ultrasonography, the appropriate screening interval for MRIB is not yet determined.
4. At this time there are no data on the use of MRIB for breast cancer screening of women at high risk based on personal history of breast cancer, previous chest irradiation, lobular carcinoma in situ, atypical hyperplasia, or mutations other than BRCA.
5. Limitations of MRIB are related to technical, professional, and biological factors, as well as availability. Standards related to equipment, scanning protocols, interpretation, MRI-guided biopsies and MRI-guided needle localization are presently under development by the American College of Radiology and other societies. Implementation of these performance standards is expected to continually increase the importance of MRIB.
6. Women should be advised of the benefits and limitations of MRIB.
7. The guideline committee supports and encourages prospective clinical trials of MRIB for surveillance of women at high risk for breast cancer.

None provided

The type of evidence supporting the recommendations is not specifically stated.

• American Society of Breast Disease. The use of magnetic resonance imaging of the breast (MRIB) for screening of women at high risk of breast cancer. Dallas (TX): American Society of Breast Disease; 2004 Jun 28. 5 p. [40 references]

Not applicable: The guideline was not adapted from another source.

2004 Jun 28

American Society of Breast Disease - Disease Specific Society

American Society of Breast Disease

Expert Committee on Screening of Women at High Risk of Breast Cancer

Committee Members: Amy P. Early, MD, Buffalo Medical Group, Williamsville, New York, Chair; Julio A. Ibarra, MD, Orange Coast Memorial Medical Center, Fountain Valley, California; Kenneth H. Eckert, Jr., MD, Kaleida Breast Center, Women and Children’s Hospital, Buffalo, New York; David M. Euhus, MD, University of Texas Southwestern Medical Center, Dallas, Texas; Steven E. Harms, MD, University of Arkansas, Little Rock, Arkansas; Richard W. Reitherman, MD, Newport Diagnostic Center, La Canada, California; Eva Rubin, MD, Montgomery Radiology Associates, Montgomery, Alabama

Not stated

This is the current release of the guideline.

Electronic copies: Not available at this time.

Print copies: Available from the American Society of Breast Disease, PO Box 140186, Dallas, Texas 75214; Phone: (214) 368-6836

None available

None available

This NGC summary was completed by ECRI on August 16, 2004. The information was verified by the guideline developer on September 14, 2004.

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.